Combined blockade of VEGF, Angiopoietin-2, and PD1 reprograms glioblastoma endothelial cells into quasi-antigen-presenting cells
暂无分享,去创建一个
R. Jain | Nan Wang | D. Fukumura | Z. Amoozgar | P. Andersson | S. Subudhi | G. Ferraro | Peigen Huang | Rong En Tay | K. Kawaguchi | Hye-Jung Kim | Pin-Ji Lei | S. Krishnan | I. Gomes-Santos | Jun Ren | Zohreh Amoozgar | Patrik Andersson | Hye-Jung Kim
[1] R. Jain,et al. The local microenvironment matters in preclinical basic and translational studies of cancer immunology and immunotherapy. , 2022, Cancer cell.
[2] A. Regev,et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours , 2022, Nature.
[3] J. Scoazec,et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. , 2022, Cancer cell.
[4] Susan M. Schlenner,et al. Anticancer immunotherapies transition postcapillary venules into high-endothelial venules that generate TCF1+ T lymphocyte niches through a feed-forward loop , 2021, bioRxiv.
[5] Susan M. Chang,et al. Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] R. Jain,et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas , 2021, Nature Communications.
[7] S. Beck,et al. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion , 2021, Cell.
[8] A. Ribas,et al. IFNg is Critical for CAR T Cell Mediated Myeloid Activation and Induction of Endogenous Immunity. , 2021, Cancer discovery.
[9] A. Griffioen,et al. Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes , 2021, Nature Reviews Clinical Oncology.
[10] T. Golub,et al. Fatty acid synthesis is required for breast cancer brain metastasis , 2021, Nature Cancer.
[11] E. Bremer,et al. The Role of Macrophages in Cancer Development and Therapy , 2021, Cancers.
[12] M. Lim,et al. Combination immunotherapy strategies for glioblastoma , 2021, Journal of Neuro-Oncology.
[13] M. Weller,et al. A vasculature-centric approach to developing novel treatment options for glioblastoma , 2021, Expert opinion on therapeutic targets.
[14] P. Sorger,et al. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma , 2020, Clinical Cancer Research.
[15] P. Wen,et al. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma , 2020, Clinical Cancer Research.
[16] David T. Paik,et al. Single-Cell RNA-seq Unveils Unique Transcriptomic Signatures of Organ-Specific Endothelial Cells. , 2020, Circulation.
[17] W. Lee,et al. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity , 2020, Experimental & Molecular Medicine.
[18] Sean P. Palecek,et al. Transcriptomic comparison of human and mouse brain microvessels , 2020, Scientific Reports.
[19] M. Weller,et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.
[20] S. Mitragotri,et al. Cellular backpacks for macrophage immunotherapy , 2020, Science Advances.
[21] O. Elemento,et al. Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas. , 2020, Cancer discovery.
[22] B. Engelhardt,et al. Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation , 2020, Vascular biology.
[23] L. Bolund,et al. Single-Cell Transcriptome Atlas of Murine Endothelial Cells , 2020, Cell.
[24] A. Malik,et al. Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation , 2020, eLife.
[25] Y. Kienast,et al. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy , 2019, Proceedings of the National Academy of Sciences.
[26] W. Muller,et al. Endothelial Cell Calcium Signaling During Barrier Function and Inflammation. , 2019, The American journal of pathology.
[27] Hunter S. Futch,et al. Organotypic brain slice cultures to model neurodegenerative proteinopathies , 2019, Molecular Neurodegeneration.
[28] K. Plate,et al. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF , 2019, Cancer Immunology Research.
[29] L. Rénia,et al. Lung endothelial cell antigen cross-presentation to CD8+T cells drives malaria-associated lung injury , 2019, Nature Communications.
[30] G. Coukos,et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.
[31] Christopher M. Jackson,et al. Mechanisms of immunotherapy resistance: lessons from glioblastoma , 2019, Nature Immunology.
[32] M. Weller,et al. How we treat glioblastoma , 2019, ESMO Open.
[33] T. Renné,et al. A systems-based map of human brain cell-type enriched genes and malignancy-associated endothelial changes , 2019, bioRxiv.
[34] A. Brandes,et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. , 2019, The Lancet. Oncology.
[35] S. Funk,et al. EphA2 stimulates VCAM-1 expression through calcium-dependent NFAT1 activity. , 2018, Cellular signalling.
[36] Ying Sun,et al. Single-cell RNA sequencing of mouse brain and lung vascular and vessel-associated cell types , 2018, Scientific Data.
[37] M. Kasahara,et al. The immunoproteasome and thymoproteasome: functions, evolution and human disease , 2018, Nature Immunology.
[38] Jie-Young Song,et al. Rsad2 is necessary for mouse dendritic cell maturation via the IRF7-mediated signaling pathway , 2018, Cell Death & Disease.
[39] A. De Luca,et al. The Role of Endothelial Ca2+ Signaling in Neurovascular Coupling: A View from the Lumen , 2018, International journal of molecular sciences.
[40] Dai Fukumura,et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.
[41] R. Kerbel,et al. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa , 2018, Nature Reviews Clinical Oncology.
[42] D. Bigner,et al. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma , 2018, Clinical Cancer Research.
[43] M. Zaidi,et al. TAMeless traitors: macrophages in cancer progression and metastasis , 2017, British Journal of Cancer.
[44] R. Martuza,et al. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. , 2017, Cancer cell.
[45] M. Gessler,et al. Gene expression profiles of brain endothelial cells during embryonic development at bulk and single-cell levels , 2017, Science Signaling.
[46] A. Giobbie-Hurder,et al. Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes , 2017, Cancer Immunology Research.
[47] R. Weichselbaum,et al. Tumour ischaemia by interferon-γ resembles physiological blood vessel regression , 2017, Nature.
[48] D. Hanahan,et al. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation , 2017, Science Translational Medicine.
[49] Y. Kienast,et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade , 2017, Science Translational Medicine.
[50] A. Giobbie-Hurder,et al. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy , 2016, Cancer Immunology Research.
[51] R. Jain,et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages , 2016, Proceedings of the National Academy of Sciences.
[52] Jennie W. Taylor,et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival , 2016, Proceedings of the National Academy of Sciences.
[53] G. Tiegs,et al. Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells , 2016, Cellular & Molecular Immunology.
[54] Abhishek D. Garg,et al. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma , 2016, Science Translational Medicine.
[55] M. Sanson,et al. Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma , 2016, Cancer investigation.
[56] Kristen L. Jones,et al. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model , 2015, Cancer Immunology Research.
[57] M. Falasca,et al. CD31 signals confer immune privilege to the vascular endothelium , 2015, Proceedings of the National Academy of Sciences.
[58] C. Humpel,et al. ORGANOTYPIC BRAIN SLICE CULTURES: A REVIEW , 2015, Neuroscience.
[59] C. Poh,et al. Activated Brain Endothelial Cells Cross-Present Malaria Antigen , 2015, PLoS pathogens.
[60] T. Rőszer,et al. Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms , 2015, Mediators of inflammation.
[61] C. James,et al. Immunocompetent murine models for the study of glioblastoma immunotherapy , 2014, Journal of Translational Medicine.
[62] B. Rosen,et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation , 2013, Proceedings of the National Academy of Sciences.
[63] H. Wakimoto,et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model , 2013, Proceedings of the National Academy of Sciences.
[64] Stefan Liebner,et al. Wnt signaling in the vasculature. , 2013, Experimental cell research.
[65] R. Jain,et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy , 2012, Proceedings of the National Academy of Sciences.
[66] A. Oxenius,et al. Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination , 2011, Proceedings of the National Academy of Sciences.
[67] S. Rabkin,et al. Cancer Stem Cell-Like Cells Derived from Malignant Peripheral Nerve Sheath Tumors , 2011, PloS one.
[68] Thomas Benner,et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] R. Jain,et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] Jordan S. Pober,et al. Endothelial Cells in Allograft Rejection , 2008, Transplantation.
[71] Andrew P. McMahon,et al. Canonical Wnt Signaling Regulates Organ-Specific Assembly and Differentiation of CNS Vasculature , 2008, Science.
[72] W. Mandemakers,et al. A Novel Purification Method for CNS Projection Neurons Leads to the Identification of Brain Vascular Cells as a Source of Trophic Support for Corticospinal Motor Neurons , 2008, The Journal of Neuroscience.
[73] J. Reed,et al. Birc2 (cIap1) regulates endothelial cell integrity and blood vessel homeostasis , 2007, Nature Genetics.
[74] M. Del Vecchio,et al. Interleukin-12: Biological Properties and Clinical Application , 2007, Clinical Cancer Research.
[75] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[76] E. Wherry,et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin , 2005, Nature Immunology.
[77] Peter Cresswell,et al. Mechanisms of MHC class I‐restricted antigen processing and cross‐presentation , 2005, Immunological reviews.
[78] T. Waldmann,et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[79] Lei Xu,et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.
[80] F. Marelli-Berg,et al. Antigen presentation by the endothelium: a green light for antigen-specific T cell trafficking? , 2004, Immunology letters.
[81] W. Aird,et al. Endothelial cells present antigens in vivo , 2004, BMC Immunology.
[82] A. Valujskikh,et al. Emerging roles of endothelial cells in transplant rejection. , 2003, Current opinion in immunology.
[83] J. Norton,et al. The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target. , 2002, Cancer research.
[84] Wolfgang Weninger,et al. Migratory Properties of Naive, Effector, and Memory Cd8+ T Cells , 2001, The Journal of experimental medicine.
[85] C. F. Bennett,et al. A Constitutive Cytoprotective Pathway Protects Endothelial Cells from Lipopolysaccharide-induced Apoptosis* , 2001, The Journal of Biological Chemistry.
[86] B. Barres,et al. Induction of Astrocyte Differentiation by Endothelial Cells , 2001, The Journal of Neuroscience.
[87] P. Knolle,et al. Liver sinusoidal endothelial cells: a new type of organ-resident antigen-presenting cell. , 2001, Archivum immunologiae et therapiae experimentalis.
[88] N. Bunnett,et al. Substance P activates coincident NF-AT- and NF-kappa B-dependent adhesion molecule gene expression in microvascular endothelial cells through intracellular calcium mobilization. , 1999, Journal of immunology.
[89] A. Lichtman,et al. Endothelial antigen presentation: stimulation of previously activated but not naïve TCR-transgenic mouse T cells. , 1998, Cellular immunology.
[90] D. Clapham,et al. Calcium signaling , 1995, Cell.
[91] F. Lemonnier,et al. Beta 2-microglobulin restriction of antigen presentation. , 1990, Nature.